Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 228 Thoracic 85 Head & Neck 64 Breast 61 CNS 57 Sarcoma 36 Gynecologic 32 Genitourinary 26 Dermatologic 20 Endocrine 10 Tumor-Agnostic 8 Other solid neoplasm 4 Other neoplasm 1 Other hematologic neoplasm 1 Other 1 NET 1 Lymphoid 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1 Neoplasm Metastasis 1

Interventions

lutetium Lu 177 dotatate 32 Everolimus 19 Magnetic Resonance Spectroscopy 14 gallium Ga 68 dotatate 12 Temozolomide 12 Nivolumab 11 Capecitabine 10 pembrolizumab 9 lanreotide 9 cabozantinib 8 Positron Emission Tomography Computed Tomography 8 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 Ga(III)-DOTATOC 7 3-Iodobenzylguanidine 7 Somatostatin 6 Octreotide 6 Lutetium-177 6 Carboplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 telotristat ethyl 5 surufatinib 5 lenvatinib 5 Ipilimumab 5 Fluorodeoxyglucose F18 5 pasireotide 4 copper dotatate CU-64 4 avelumab 4 Single Photon Emission Computed Tomography Computed Tomography 4 Positron-Emission Tomography 4 Bevacizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Surgical Procedures, Operative × NET × Clear all

NCT04066322 2019-09-24

RMPanNET

Fudan University

Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡